IDEAYA Biosciences, Inc. (IDYA)
32.89
-1.07
(-3.15%)
USD |
NASDAQ |
Oct 29, 16:00
32.90
+0.01
(+0.03%)
After-Hours: 06:58
IDEAYA Biosciences Enterprise Value : 2.370B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 2.370B |
| October 28, 2026 | 2.473B |
| October 27, 2026 | 2.429B |
| October 26, 2026 | 2.369B |
| October 23, 2026 | 2.546B |
| October 22, 2026 | 2.681B |
| October 21, 2026 | 2.619B |
| October 20, 2026 | 2.608B |
| October 19, 2026 | 2.459B |
| October 16, 2026 | 2.366B |
| October 15, 2026 | 2.463B |
| October 14, 2026 | 2.464B |
| October 13, 2026 | 2.502B |
| October 12, 2026 | 2.676B |
| October 09, 2026 | 2.680B |
| October 08, 2026 | 2.676B |
| October 07, 2026 | 2.695B |
| October 06, 2026 | 2.731B |
| October 05, 2026 | 2.868B |
| October 02, 2026 | 2.801B |
| October 01, 2026 | 2.844B |
| September 30, 2026 | 2.903B |
| September 29, 2026 | 2.849B |
| September 28, 2026 | 2.884B |
| September 25, 2026 | 2.736B |
| Date | Value |
|---|---|
| September 24, 2026 | 2.741B |
| September 23, 2026 | 2.811B |
| September 22, 2026 | 3.027B |
| September 21, 2026 | 2.946B |
| September 18, 2026 | 2.902B |
| September 17, 2026 | 2.921B |
| September 16, 2026 | 2.837B |
| September 15, 2026 | 2.830B |
| September 14, 2026 | 2.866B |
| September 11, 2026 | 2.823B |
| September 10, 2026 | 2.810B |
| September 09, 2026 | 2.896B |
| September 08, 2026 | 2.944B |
| September 04, 2026 | 3.042B |
| September 03, 2026 | 3.052B |
| September 02, 2026 | 3.072B |
| September 01, 2026 | 3.051B |
| August 31, 2026 | 3.065B |
| August 28, 2026 | 3.066B |
| August 27, 2026 | 3.226B |
| August 26, 2026 | 3.208B |
| August 25, 2026 | 3.294B |
| August 24, 2026 | 3.059B |
| August 21, 2026 | 3.024B |
| August 20, 2026 | 2.970B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 915.91M |
| Xencor, Inc. | 1.885B |
| BioMarin Pharmaceutical, Inc. | 14.47B |
| MediciNova, Inc. | 43.61M |
| Viking Therapeutics, Inc. | 2.720B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -112.45M |
| Revenue (Quarterly) | 8.857M |
| Total Expenses (Quarterly) | 121.31M |
| EPS Diluted (Quarterly) | -1.222 |
| Gross Profit Margin (Quarterly) | 87.21% |
| Profit Margin (Quarterly) | -1.27K% |
| Earnings Yield | -5.91% |
| Normalized Earnings Yield | -5.908 |